Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
about
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Hans Christian Andersen and the Value of New Cancer Treatments.Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada.Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.Healthcare Priority-Setting: Chat-Ting Is Not Enough Comment on "Swiss-CHAT: Citizens Discuss Priorities for Swiss Health Insurance Coverage"
P2860
Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Clinical benefit, price and ap ...... anced solid cancer, 2000-2015.
@en
Clinical benefit, price and ap ...... anced solid cancer, 2000-2015.
@nl
type
label
Clinical benefit, price and ap ...... anced solid cancer, 2000-2015.
@en
Clinical benefit, price and ap ...... anced solid cancer, 2000-2015.
@nl
prefLabel
Clinical benefit, price and ap ...... anced solid cancer, 2000-2015.
@en
Clinical benefit, price and ap ...... anced solid cancer, 2000-2015.
@nl
P2093
P2860
P50
P356
P1433
P1476
Clinical benefit, price and ap ...... anced solid cancer, 2000-2015.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDX053
P577
2017-05-01T00:00:00Z